Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Bill Toll-Free Adverse Event Hotline Is Of Concern To Pharmacy

Executive Summary

The retail pharmacy trade associations are urging the House leadership to delete language creating an adverse event reporting hotline from the pediatric exclusivity bill

You may also be interested in...



Pediatric Prozac Phase IV Commitments Will Test Exclusivity Incentive

Lilly's Phase IV commitments for additional research on pediatric use of Prozac will serve as a high-profile test of FDA's pediatric exclusivity incentive

Pediatric Prozac Phase IV Commitments Will Test Exclusivity Incentive

Lilly's Phase IV commitments for additional research on pediatric use of Prozac will serve as a high-profile test of FDA's pediatric exclusivity incentive

House Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Tauzin Says

Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated

Related Content

UsernamePublicRestriction

Register

PS038790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel